Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up

A follow-up study involving veterans with type 2 diabetes at high risk for cardiovascular disease showed no legacy effect after 5.6 years of intensive glucose lowering. The risk of major cardiovascular events was not reduced over a 13.6-year period, and a mortality benefit or improvement in quality...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 380; no. 23; pp. 2215 - 2224
Main Authors Reaven, Peter D, Emanuele, Nicholas V, Wiitala, Wyndy L, Bahn, Gideon D, Reda, Domenic J, McCarren, Madeline, Duckworth, William C, Hayward, Rodney A
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 06.06.2019
Subjects
Amputation
Blood Glucose - analysis
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - mortality
Cardiovascular Diseases - prevention & control
Cerebral infarction
Congestive heart failure
Death
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Female
Follow-Up Studies
Gangrene
Glucose
Hemoglobin
Humans
Hyperglycemia - prevention & control
Hypoglycemic Agents - administration & dosage
Ischemia
Male
Medical records
Middle Aged
Mortality
Myocardial infarction
Pharmaceuticals
Quality of Life
Randomized Controlled Trials as Topic
Statistical analysis
Veterans
Online AccessGet full text

Cover

More Information
Summary:A follow-up study involving veterans with type 2 diabetes at high risk for cardiovascular disease showed no legacy effect after 5.6 years of intensive glucose lowering. The risk of major cardiovascular events was not reduced over a 13.6-year period, and a mortality benefit or improvement in quality of life over 15 years was not seen.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
A complete list of the investigators in the Veterans Affairs Diabetes Trial (VADT) is provided in the Supplementary Appendix, available at NEJM.org.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1806802